Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of systematic versus guided radioiodine use after thyroidectomy in intermediate-risk differentiated thyroid cancer
2024-514603-34-00Phase 3Authorised
- Sponsor
- Centre François Baclesse
- Start
- Jun 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of sodium iodide I-131 in well-differentiated thyroid cancer (WDTC) (2 arms), sponsored by Centre François Baclesse. Primary endpoint: Excellent response rate at 3 years. Planned start Jun 2024; status: authorised.
02
Drugs
sodium iodide I-131
03
Conditions
well-differentiated thyroid cancer (WDTC)
Beyond the preview
Go deeper on 2024-514603-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514603-34-00.